March 30, 2017 8:03 AM ET

Biotechnology

Company Overview of Acceleron Pharma Inc.

Company Overview

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. Its therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. The company’s therapeutic candidates also include Dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy. It has collaboration, license, and option agreement with Celgene Corporation. The c...

128 Sidney Street

Cambridge, MA 02139

United States

Founded in 2003

121 Employees

Phone:

617-649-9200

Fax:

617-649-9988

Key Executives for Acceleron Pharma Inc.

Chief Financial Officer, Senior Vice President and Treasurer
Age: 60
Total Annual Compensation: $353.3K
Chief Operating Officer and Executive Vice President
Age: 47
Total Annual Compensation: $404.1K
Chief Medical Officer and Executive Vice President
Age: 60
Total Annual Compensation: $413.0K
Senior Vice President of Business Development and General Counsel
Age: 45
Total Annual Compensation: $345.1K
Compensation as of Fiscal Year 2015.

Acceleron Pharma Inc. Key Developments

Acceleron Pharma, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016

Acceleron Pharma Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported collaboration revenue of $3,369,000 against $3,804,000 a year ago. Loss from operations was $21,986,000 against $18,115,000 a year ago. Loss before income tax was $19,244,000 compared to $27,082,000 a year ago. Net loss was $19,288,000 against $27,082,000 a year ago. Net loss per share applicable to common stockholders-basic and diluted was $0.51 against $0.81 a year ago. For the year, the company reported collaboration revenue of $27,771,000 against $18,097,000 a year ago. Loss from operations was $66,106,000 against $60,879,000 a year ago. Loss before income tax was $56,990,000 compared to $63,894,000 a year ago. Net loss was $57,014,000 against $63,894,000 a year ago. Net loss per share applicable to common stockholders-basic and diluted was $1.52 against $1.92 a year ago.

Acceleron Pharma Inc. Presents at Cowen and Company 37th Annual Health Care Conference, Mar-06-2017 02:00 PM

Acceleron Pharma Inc. Presents at Cowen and Company 37th Annual Health Care Conference, Mar-06-2017 02:00 PM. Venue: The Boston Marriott Copley Place, 110 Huntington Avenue, Boston, Massachusetts, United States.

Acceleron Pharma Inc., Q4 2016 Earnings Call, Mar 01, 2017

Acceleron Pharma Inc., Q4 2016 Earnings Call, Mar 01, 2017

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Acceleron Pharma Inc., please visit www.acceleronpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.